60 Participants Needed

Wearable tES for Insomnia

AP
ST
Overseen BySonja T Skeete, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Uniformed Services University of the Health Sciences
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this study is to investigate the ability of a translational device, Teledyne PeakSleep, to reduce sleep onset latency, reduce time awake after sleep onset and improve restfulness and the subjective benefits of sleep in a patient population with insomnia via transcranial direct current stimulation (tDCS) applied to frontal lobe circuits.

Will I have to stop taking my current medications?

If you are currently taking medication for insomnia, you will need to stop treatment for at least 2 weeks before joining the study. If you are on other medications, especially those related to psychiatric conditions, you should not have had any changes in the last 4 weeks.

What data supports the effectiveness of the treatment PeakSleep for insomnia?

Research shows that transcranial direct current stimulation (tDCS), a component of PeakSleep, can improve sleep quality and efficiency in people with insomnia. Studies have found that tDCS can increase sleep duration and reduce the time it takes to fall asleep, suggesting it may be a promising treatment for sleep issues.12345

Is transcranial direct current stimulation (tDCS) safe for humans?

Transcranial direct current stimulation (tDCS) is generally considered safe for humans, with most studies reporting only mild and temporary side effects. Medical-grade tDCS devices are designed to minimize risks, and there is no evidence of serious or intolerable side effects.16789

How is the treatment PeakSleep different from other treatments for insomnia?

PeakSleep, a type of transcranial direct current stimulation (tDCS), is unique because it uses a non-invasive electrical brain stimulation method to improve sleep quality by modulating brain activity. Unlike traditional sedative drugs, it offers a personalized approach by adjusting the stimulation frequencies based on individual brain patterns, potentially leading to better sleep duration and faster sleep onset.123410

Research Team

JK

John K Werner, MD PhD

Principal Investigator

Uniformed Services University of the Health Sciences

Eligibility Criteria

This trial is for adults aged 18-70 with sleep onset insomnia who are Tricare eligible. They can have had non-drug therapy like CBT if it ended over two weeks ago and haven't used sleep meds recently. Excluded are those with hearing aids, metal implants (except dental), tattoos on the head, substance abuse issues, unstable psychiatric disorders, recent major surgery or hospitalization, neurological conditions, or excessive alcohol intake.

Inclusion Criteria

I have been diagnosed with difficulty falling asleep.
I have been diagnosed with insomnia.
I stopped any non-drug therapy, like CBT, more than 14 days ago.
See 2 more

Exclusion Criteria

Non-removable metal anywhere in the body except bridges or fillings
You drink more than 10 alcoholic drinks every week.
You have had thoughts of hurting yourself or thinking about suicide in the past two weeks.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
1 visit (in-person)

Baseline

Collection of baseline self-reported data and actigraphy device training

2 weeks
1 visit (in-person)

Treatment

Participants use the PeakSleep wearable neurotechnology prototype headband for tDCS treatment

6 weeks
4 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Treatment Details

Interventions

  • PeakSleep
  • Sham
Trial OverviewThe study tests a device called PeakSleep against a sham (fake) treatment to see if it helps people with insomnia fall asleep faster and feel more rested. It uses tDCS applied to the frontal lobe of the brain to potentially improve sleep quality.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: StimulationActive Control1 Intervention
Short duration repetitive (SDR-) tES with a frequency of 0.75Hz
Group II: Sham ConditionPlacebo Group1 Intervention
Sham condition using a low current amplitude at 25 Hz.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Uniformed Services University of the Health Sciences

Lead Sponsor

Trials
130
Recruited
91,100+

Findings from Research

A 52-year-old woman with chronic insomnia showed significant improvement in sleep quality and emotional stability after receiving a combination of repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) over 20 treatment sessions.
The improvements were measured using various clinical scales and were maintained one month after treatment, indicating that this combined approach is feasible, tolerable, and safe for treating chronic insomnia.
Transcranial magnetic stimulation combined with transcranial direct current stimulation in patients with chronic insomnia: a case report.Zhou, Q., Liu, Z., Zhao, S., et al.[2023]
In a study involving nine patients with chronic insomnia, transcranial alternating stimulation (tACS) showed promising effects on sleep parameters, including improvements in sleep quality, sleep duration, and daytime sleepiness, although not all results reached statistical significance.
The stimulation, applied for 5 minutes at a low current, also led to reductions in spontaneous and total arousals, suggesting that tACS may enhance overall sleep stability and quality in patients with insomnia.
Transcranial Alternating Current Stimulation (tACS) as a Treatment for Insomnia.Motamedi, GK., Jeliazkov, PG., Oyegbile-Chidi, TO., et al.[2023]
A study involving 25 participants showed that personalized transcranial alternating current stimulation (tACS) significantly increased sleep duration by an average of 22 minutes compared to a control condition, highlighting its potential as a non-invasive sleep intervention.
Personalized tACS also reduced the time taken to fall asleep by 28% compared to fixed stimulation, suggesting that tailoring stimulation to individual brain activity may enhance sleep quality, especially for those with insomnia.
Personalized transcranial alternating current stimulation improves sleep quality: Initial findings.Ayanampudi, V., Kumar, V., Krishnan, A., et al.[2023]

References

Transcranial magnetic stimulation combined with transcranial direct current stimulation in patients with chronic insomnia: a case report. [2023]
Transcranial Alternating Current Stimulation (tACS) as a Treatment for Insomnia. [2023]
Personalized transcranial alternating current stimulation improves sleep quality: Initial findings. [2023]
Slow oscillating transcranial direct current stimulation during sleep has a sleep-stabilizing effect in chronic insomnia: a pilot study. [2018]
The Efficacy of Transcranial Current Stimulation Techniques to Modulate Resting-State EEG, to Affect Vigilance and to Promote Sleepiness. [2020]
A Systematic Review on the Acceptability and Tolerability of Transcranial Direct Current Stimulation Treatment in Neuropsychiatry Trials. [2018]
Physics of Transcranial Direct Current Stimulation Devices and Their History. [2022]
Non-invasive cortical stimulation: Transcranial direct current stimulation (tDCS). [2022]
[The effect of transcranial direct current stimulation on dysfunction of bilateral posterior cingulate cortex after sleep deprivation: a preliminary study]. [2020]
The Effects of Anodal Transcranial Direct Current Stimulation on Sleep Time and Efficiency. [2020]